Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-03-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司独立董事2024年度述职报告（沈永建）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for Jinling Pharmaceutical Co., Ltd. It details the independent director's activities, attendance at board meetings, committee work, communication with shareholders, and oversight responsibilities during the 2024 fiscal year. It includes evaluations of financial reports and internal controls but does not itself contain financial statements or detailed financial data. The document is a narrative report on the independent director's duties and observations rather than a financial report or regulatory filing. It is not an announcement of voting results, management changes, or legal proceedings. It fits best as a Management Report or similar detailed explanation of governance and oversight activities. However, since the exact category for independent director reports is not explicitly listed, and the document focuses on the independent director's work and governance oversight, the closest fitting category is "Board/Management Information (MANG)" which covers announcements related to board and senior management activities. The document length is 4254 characters, which is substantial but not a full financial report. Therefore, the classification is MANG with high confidence.
2025-03-28 Chinese
证券投资专项说明
Regulatory Filings Classification · 95% confidence The document is a special statement from the board of directors of Jinling Pharmaceutical Co., Ltd. regarding the company's securities investment situation for the year 2024. It provides detailed information on securities investment holdings, investment income, and internal control measures related to securities investment. The document references disclosures in the 2024 semi-annual and annual reports but itself is a standalone explanation focused on securities investment. It does not contain comprehensive financial statements or full annual report content, nor is it a brief announcement or certification. Given the focus on securities investment details and internal controls, this fits best under Regulatory Filings (RNS) as a specialized disclosure that does not fit other categories like Annual Report or Interim Report.
2025-03-28 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled "专项报告" (Special Report) concerning non-operating fund occupation and other related party fund transactions of Jinling Pharmaceutical Co., Ltd. It includes detailed financial data tables about fund occupation and related party transactions for the fiscal year 2024, with audit opinions and certifications from a licensed accounting firm. The document references compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is not a full annual report but a standalone audit-related report focusing on specific financial audit matters related to non-operating funds and related party transactions. This fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. The document length (15,000 characters) and detailed financial data support this classification with high confidence. FY 2024
2025-03-28 Chinese
年度募集资金使用鉴证报告
Regulatory Filings
2025-03-28 Chinese
金陵药业关联方资金报告
Regulatory Filings
2025-03-28 Chinese
金陵药业股份有限公司2024年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" (2024 Supervisory Board Work Report) of Jinling Pharmaceutical Co., Ltd. It details the supervisory board's activities, including oversight of company operations, financial checks, internal controls, related party transactions, and information disclosure for the year 2024. It references the audit report issued by an accounting firm but does not itself contain financial statements or audit opinions. The document is a detailed report on the supervisory board's work and opinions for the year, which aligns with the nature of an Audit Report / Information (AR) filing, as it focuses on supervisory and audit-related oversight rather than being a full annual report or other category. The length (3513 characters) and content indicate it is a substantive report, not a brief announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2024
2025-03-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.